| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Department of Radiology, University of Vienna, Waehringer Gürtel 18-20,
A-1090 Vienna, Austria.
2 Department of Radiology, University of Washington, Harborview Medical Center,
Box 359728, Seattle, WA 98104-2499.
3 Department of Radiology, Klinikum Karlsruhe, Moltkestr. 90, D-76133 Karlsruhe,
Germany.
4 Department of Surgery, University of Vienna, A-1090 Vienna, Austria.
5 Department of Pathology, University of Vienna, A-1090 Vienna, Austria.
6 Department of Nuclear Medicine, University of Vienna, A-1090 Vienna,
Austria.
7 Department of Radiology, Duke University Medical Center, Durham, NC
27710.
OBJECTIVE. The objective of our study was to describe the functional and differential uptake features of atypical focal nodular hyperplasia using different MR contrast agents and to evaluate their potential role in the diagnosis and characterization of focal nodular hyperplasia.
MATERIALS AND METHODS. Contrast-enhanced MR images of 45 patients with 85 focal nodular hyperplasia lesions were retrospectively reviewed. In these patients, sonographic findings were nonspecific (n = 37), or CT features were inconclusive (n = 8). Non—liver specific gadolinium chelates were used in 18 patients (48 lesions) suspected of having either focal nodular hyperplasia or hemangioma. The following liver-specific agents were used in patients with suspected focal nodular hyperplasia or metastases: mangafodipir trisodium, 30 patients (55 lesions); ferumoxides, six patients (16 lesions); and SHU 555 A, six patients (six lesions). Individual lesions were quantified by signal intensity and assessed qualitatively by homogeneity, contrast enhancement, and presence of a central scar.
RESULTS. At unenhanced MR imaging, the triad of homogeneity, isointensity, and central scar was found in 22% of the focal nodular hyperplasia lesions. On mangafodipir trisodium—enhanced T1-weighted images, all focal nodular hyperplasia lesions showed contrast uptake: in 64% of the lesions, uptake was equal to parenchyma; 25%, greater than the parenchyma; and 11%, less than the parenchyma. On iron oxide—enhanced T2-weighted images, all focal nodular hyperplasia lesions showed uptake of the contrast agent, but contrast uptake in the lesions was less than in the surrounding parenchyma. Dynamic gadolinium chelate—enhanced MR imaging showed early and vigorous enhancement of focal nodular hyperplasia lesions with rapid washout in 88%. Atypical imaging features of the lesions included hyperintensity on T1-weighted images, necrosis and hemorrhage, and inhomogeneous or only minimal contrast uptake.
CONCLUSION. For patients in whom the diagnosis of focal nodular hyperplasia cannot be established on unenhanced or gadolinium-enhanced MR imaging, homogeneous uptake of liver-specific contrast agent with better delineation of central scar may help to make a confident diagnosis of focal nodular hyperplasia.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Ferlicot, H. Kobeiter, J. T. Van Nhieu, D. Cherqui, D. Dhumeaux, D. Mathieu, and E. S. Zafrani MRI of Atypical Focal Nodular Hyperplasia of the Liver: Radiology-Pathology Correlation Am. J. Roentgenol., May 1, 2004; 182(5): 1227 - 1231. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Levy Invited Commentary RadioGraphics, January 1, 2004; 24(1): 18 - 19. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
